World

United Nations vehicle in Gaza hit by Israeli gunfire

Aug 29, 2024

New York [US], August 29: The United Nations has reported that one of its humanitarian vehicles in Gaza, marked with the organisation's insignia, was fired upon 10 times by Israeli forces, including shots targeting its front windows, while it was part of a convoy fully coordinated with the Israeli army.
UN spokesperson Stephane Dujarric stated today, Wednesday, that the two staff members in the vehicle were unharmed. He referred to comments made by a senior UN official, who requested anonymity, two days ago to journalists about the need for armoured vehicles in Gaza.
The incident underscored the importance of this, as the armoured vehicle saved the lives of the staff members and revealed that current coordination mechanisms are ineffective.
Dujarric assured that the UN would continue to work with the Israeli army to ensure that such incidents do not recur.
The international spokesperson stressed the necessity for all parties to respect international humanitarian law at all times, which includes the protection of civilians and the provision of their basic needs, such as food, water, shelter, and health care, wherever they are in Gaza.
He clarified that this applies to those under evacuation orders, whether they have moved or not, indicating that those who leave must be given sufficient time to depart, safe routes, and safe areas to which they can go.
Source: Emirates News Agency

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025